No connection

Search Results

HCWB

BEARISH
$0.36 Live
HCW Biologics Inc. · NASDAQ
Target $2.0 (+448.7%)
$0.25 52W Range $17.8

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 11, 2026
Market cap
$2.45M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
2.46
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
98%
HCWB exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.11 and a catastrophic revenue collapse of -93.20% YoY. With a negative Price-to-Book ratio (-0.45) and an operating margin of -18370.31%, the firm is effectively eroding its remaining capital. The stock's 96% decline over the past year reflects a market pricing in a high probability of insolvency.

Key Strengths

Positive Gross Margin (20%)
Single analyst target price ($2.00) suggests theoretical upside
Recent 1-week short-term price bounce (+36%)
Year-over-year EPS growth is technically positive due to a lower base of losses
Operating in the high-growth Biotechnology sector

Key Risks

Extreme liquidity risk (Current Ratio 0.11)
Catastrophic revenue decline (-93.20% YoY)
Negative shareholder equity (Price/Book -0.45)
High risk of bankruptcy or massive equity dilution
Consistent failure to meet earnings estimates (0/4 beats in last 4 quarters)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
1
Weak
Value
0
Future
0
Past
5
Health
0
Dividend
0
AI Verdict
High Risk of Insolvency
Key drivers: Piotroski F-Score 1/9, Current Ratio 0.11, Revenue Growth -93.20%, Negative Book Value
Confidence
95%
Value
0/100

P/S and P/B metrics indicate the stock is fundamentally overpriced relative to its distressed assets.

Positives
No standout positives identified.
Watchpoints
  • Price/Sales of 45.26 is exorbitant for a declining company
  • Negative Price/Book ratio
  • No Graham Number available due to negative earnings/equity
Future
0/100

Growth rates are in a state of collapse, making future viability unlikely without a massive capital infusion.

Positives
No standout positives identified.
Watchpoints
  • Revenue growth is crashing (-93.16% Q/Q)
  • Operating margins are deeply negative
  • Earnings surprises are consistently negative
Past
5/100

Historical price action shows a total loss of investor confidence.

Positives
No standout positives identified.
Watchpoints
  • 5-year price change of -99.9%
  • 1-year price change of -96.3%
  • Consistent earnings misses
Health
0/100

The company is in a state of severe financial distress with critical liquidity shortages.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 1/9
  • Current Ratio 0.11 (cannot cover short-term liabilities)
  • Debt/Equity of 2.46 on a negative equity base
Dividend
0/100

Dividend profile is non-existent.

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • Zero payout capacity

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.36
Analyst Target
$2.0
Upside/Downside
+448.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for HCWB and closest competitors.

Updated 2026-04-10
HCW
HCW Biologics Inc.
Primary
5Y
-99.9%
3Y
-99.4%
1Y
-96.3%
6M
-91.0%
1M
-30.6%
1W
+36.0%
HCT
Healthcare Triangle, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.9%
6M
-98.6%
1M
-21.6%
1W
-2.8%
BDR
Biodexa Pharmaceuticals Plc
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-95.1%
6M
-75.6%
1M
-24.0%
1W
-4.0%
AKA
Akanda Corp.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-96.4%
6M
-95.4%
1M
-13.6%
1W
-6.7%
ACO
Aclarion, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-82.0%
6M
-56.9%
1M
+22.9%
1W
+1.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.66
PEG Ratio
N/A
P/B Ratio
-0.45
P/S Ratio
45.26
EV/Revenue
134.82
EV/EBITDA
-0.58
Market Cap
$2.45M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -18370.3%
Gross Margin 20.0%
ROE N/A
ROA -31.19%

Growth

Revenue and earnings growth rates

Revenue Growth -93.2%
Earnings Growth N/A
Q/Q Revenue Growth -93.16%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
2.46
High debt
Current Ratio
0.11
Weak
Quick Ratio
0.09
Poor
Cash/Share
$0.29

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
20.0%
Op. Margin
-10912.3%
Net Margin
2662.8%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
7.87x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-31
$-1.02
-21.4% surprise
2025-11-14
$-2.02
-227.8% surprise
2025-08-18
$-6.79
-477.2% surprise
2025-03-28
$-3.2
-188.9% surprise

Healthcare Sector Comparison

Comparing HCWB against 226 companies in the Healthcare sector (19 bullish, 76 neutral, 131 bearish)
Debt to Equity
2.46
This Stock
vs
4.61
Sector Avg
-46.5% (Less Debt)
Revenue Growth
-93.2%
This Stock
vs
97.21%
Sector Avg
-195.9% (Slower)
Current Ratio
0.11
This Stock
vs
3.51
Sector Avg
-96.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning HCWB from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile